Репозиторий Университета

A Scientific Methodology for Expansion of Anti-Parkinson Drug Product Range Nat a lia Valeryevna Pyatigorskaya Galina Eduardovna Brkich Alexey Nikitich Pavlov Valery Vasilyevich Beregovykh Olga Vladimirovna Evdokimova Sechenov First Moscow State Medical University, Russian Fedetation, 119991, Moscow, Trubetskaya Street, 8-2 Abstract Parkinson's disease (PD) is a chronic and progressive brain disease associat ed primarily with dopamine neurons degeneration of substantia nigra. More than 10 millions of people worldwide are affected by this disease manifested by combination of hypokinesia and rigidity, shaking, and postural instability. The high prevalence of disease has determined the aim of the study: to deve lop a methodology for expansion of anti-Parkinson drug product range. The information analysis methods were used for unbiased evaluation of novel anti-Parkinson drugs creation prospects. A systemic analysis of active pharmaceu tical ingredients (AFIs) used in anti- Parkinson drug products allowed for discovery of most widely used, levodopa being the top one. A comparative assessment of dosage forms used in Parkinson’s disease treatment showed th at they are represented primarily by intestinal gels, tablets, dispersible tablets, capsules, and modified release capsules. The authors conclude, that the novel anti-Parkinson drug pr oduct should contain levodopa in form of an endonasal spray which provides optimal bioavailability due to neces sary excipients (triglycerides, sodium monohydrogen phosphate, volatile and fatty oils, herbal extracts, stabilizers, and flavouring agents).

A Scientific Methodology for Expansion of Anti-Parkinson Drug Product Range Nat a lia Valeryevna Pyatigorskaya Galina Eduardovna Brkich Alexey Nikitich Pavlov Valery Vasilyevich Beregovykh Olga Vladimirovna Evdokimova Sechenov First Moscow State Medical University, Russian Fedetation, 119991, Moscow, Trubetskaya Street, 8-2 Abstract Parkinson's disease (PD) is a chronic and progressive brain disease associat ed primarily with dopamine neurons degeneration of substantia nigra. More than 10 millions of people worldwide are affected by this disease manifested by combination of hypokinesia and rigidity, shaking, and postural instability. The high prevalence of disease has determined the aim of the study: to deve lop a methodology for expansion of anti-Parkinson drug product range. The information analysis methods were used for unbiased evaluation of novel anti-Parkinson drugs creation prospects. A systemic analysis of active pharmaceu tical ingredients (AFIs) used in anti- Parkinson drug products allowed for discovery of most widely used, levodopa being the top one. A comparative assessment of dosage forms used in Parkinson’s disease treatment showed th at they are represented primarily by intestinal gels, tablets, dispersible tablets, capsules, and modified release capsules. The authors conclude, that the novel anti-Parkinson drug pr oduct should contain levodopa in form of an endonasal spray which provides optimal bioavailability due to neces sary excipients (triglycerides, sodium monohydrogen phosphate, volatile and fatty oils, herbal extracts, stabilizers, and flavouring agents).